Compugen

$9.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.37 (+4.13%) Today

+$0.30 (+3.22%) As of 10:06 AM UTC after-hours

Why Robinhood?

You can buy or sell Compugen and other stocks, options, and ETFs commission-free!

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel. The listed name for CGEN is Compugen Ltd. Ordinary Shares.

CEO

Anat Cohen-Dayag

Employees

Headquarters

Holon, Tel Aviv

Founded

1993

Market Cap

906.79M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.02M

High Today

$9.43

Low Today

$8.50

Open Price

$9.01

Volume

3.24M

52 Week High

$19.90

52 Week Low

$5.94

CGEN News

BenzingaFeb 25

Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies

Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combinati

Analyst Ratings

100%

of 6 ratings

Buy

100%

Hold

Sell

CGEN Earnings

-$0.14

-$0.12

-$0.10

-$0.08

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.10 per share

Actual

-$0.10 per share

Replay Earnings Call